Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Debt / NOTE 2.500% 9/1
-
Market price (% of par)
-
93.47%
-
Total 13F principal
-
$215,705,000
-
Principal change
-
+$2,688,000
-
Total reported market value
-
$202,722,815
-
Number of holders
-
32
-
Value change
-
+$3,297,424
-
Number of buys
-
17
-
Number of sells
-
13
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 as of Q1 2019
As of 31 Mar 2019,
TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 was held by
32 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$215,705,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, Linden Advisors LP, WOLVERINE ASSET MANAGEMENT LLC, DLD Asset Management, LP, CNH PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, Allianz Asset Management GmbH, CAMDEN ASSET MANAGEMENT L P /CA, OAKTREE CAPITAL MANAGEMENT LP, and BARCLAYS PLC.
This page lists
32
institutional bondholders reporting positions
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.